Abstract:7 Objectives: Negative allosteric modulation of metabotropic glutamate receptor 2 (mGlu2) represents a novel specific and selective approach for treating brain disorders. Positron emission tomography (PET) imaging of mGlu2 would facilitate disease diagnosis and negative allosteric modulators (NAMs) discovery. However, few efforts have been disclosed to visualize mGlu2in vivo, indicating an unmet and urgent clinical demand. Herein we report the proof-of-concept development of PET tracers derived from NAMs for successfully imaging of mGlu2. Methods: A library seven mGlu2 NAMs 1a-1g were synthesized and subjected to the investigation of pharmacological and physicochemical properties. As a result, 1a and 1b showed excellent potency and selectivity, and then radiolabeled with 11C. The specificities of both PET tracers [11C]1a and [11C]1b were validated by in vitro autoradiography (ARG) with rat brain slices. Dynamic PET imaging were performed on normal Sprague-Dawley (SD) rats to assess the capability for brain penetration and in vivo specificity by the simplified reference tissue model (SRTM) with the pons as the reference region. Whole body biodistribution and metabolite studies were conducted in rodents to evaluate the pharmacokinetic properties of [11C]1b. Results: All of the novel compounds were synthesized in five steps with 14-20% overall yields.1a and 1b showed good binding potency (IC50 to mGlu2 30 μM), together with reasonable lipophilicity and tPSA. 11C radiolabeling were conducted within 40 min on GE TracerLab FXC, and radiochemical yields were 36.6 ± 7.3% (n = 7, [11C]1a) and 6.53 ± 1.5% (n = 10, [11C]1b) respectively, with high radiochemical purities and molar activities. ARG results showed that [11C]1b was much more specific to mGlu2 with highest radioactivity accumulated in the striatum and cerebral cortex, followed by hippocampus and cerebellum. The heterogeneous distribution was diminished by pre-incubation with the corresponding standard compounds or QCA. The non-displaceable binding potential (BPND) of [11C]1bwere calculated by PET, and the highest values were observed in striatum and cingulate cortex (0.72), followed by cerebral cortex (0.42) and hippocampus (0.48), and the lowest BPND was identified in the cerebellum (0.12) under baseline conditions. The BPND values were decreased substantially by pretreatment with 1b (41-88% reduction, 1 mg/kg) or 1a (48-90% reduction, 3 mg/kg). Biodistribution studies of [11C]1b demonstrated that high brain uptake (ca. 3.6 %ID/g) was detected after 5 min post injection, which was consistent with PET imaging data. Several peripheral organs with high mGlu2 expression were also observed with high radioactivity accumulation. Notably, metabolite analysis suggested that [11C]1bshowed excellent in vivo stability in brain with more than 99% unchanged fraction at 20 min post injection. Conclusion: We have developed [11C]1b as a potent and promising PET tracer for neuroimaging of mGlu2. Translational PET imaging in nonhuman primates are on the way and will be reported in due course.

Positron emission tomography probes targeting bromodomain and extra-terminal (BET) domains to enable in vivo neuroepigenetic imaging.

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins.

Radiosynthesis and <i>in vivo</i> evaluation of a new positron emission tomography radiotracer targeting bromodomain and extra-terminal domain (BET) family proteins

Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization

The Development and Evaluation of a Novel Highly Selective PET Radiotracer for Targeting BET BD1

Design, Synthesis, and Evaluation of Thienodiazepine Derivatives as Positron Emission Tomography Imaging Probes for Bromodomain and Extra-Terminal Domain Family Proteins

Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4

Development and Evaluation of [ 11 C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Development and Preliminary Evaluation of an Aryl 18F-Labeled PET Tracer for Imaging PDE10A

Preclinical Evaluation Of Radiolabeled Negative Allosteric Modulators For Pet Imaging Of Metabotropic Glutamate Receptor 2

Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

PET imaging of an optimized anti-PD-L1 probe 68Ga-NODAGA-BMS986192 in immunocompetent mice and non-human primates

Synthesis and Evaluation of Novel ¹⁸F Labeled 2-Pyridinylbenzoxazole and 2-Pyridinylbenzothiazole Derivatives As Ligands for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques.

Development of a Candidate 11C-Labeled Selective Phosphodiesterase 1 Radioligand for Positron Emission Tomography

Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain

Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist As a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain

Preliminary PET imaging of [11C]evobrutinib in mouse models of colorectal cancer, SARS-CoV-2, and lung damage: Radiosynthesis via base-aided palladium-NiXantphos-mediated 11C-carbonylation

Synthesis and pharmacological evaluation of [18F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971

Labeling of Bruton's Tyrosine Kinase (BTK) Inhibitor [11C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET